MALT1 inhibition is efficacious in both naïve and ibrutinib-resistant chronic lymphocytic leukemia

The clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged by the frequent emergence of resistant clones. The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B cell receptor signaling, and most resistant cases carry mutations in BTK...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Saba, Nakhle S., Wong, Deanna H., Tanios, Georges, Iyer, Jessica R., Lobelle-Rich, Patricia, Dadashian, Eman L., Liu, Delong, Fontan, Lorena, Flemington, Erik K., Nichols, Cydney M., Underbayev, Chingiz, Safah, Hana, Melnick, Ari, Wiestner, Adrian, Herman, Sarah E. M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732856/
https://ncbi.nlm.nih.gov/pubmed/28993409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-2485
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados